[1]龚建忠,韦 燕,潘琦津,等.锌剂防治鼻咽癌同步放化疗患者放射性口咽炎的效果分析[J].医学信息,2019,(17):63-67.[doi:10.3969/j.issn.1006-1959.2019.17.020]
 GONG Jian-zhong,WEI Yan,PAN Qi-jin,et al.Effect of Zinc on Prevention and Treatment of Radiation Oropharyngeal Mucositis in Patients with Nasopharyngeal Carcinoma Treated with Concurrent Chemoradiotherapy[J].Medical Information,2019,(17):63-67.[doi:10.3969/j.issn.1006-1959.2019.17.020]
点击复制

锌剂防治鼻咽癌同步放化疗患者放射性口咽炎的效果分析()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年17期
页码:
63-67
栏目:
论著
出版日期:
2019-09-01

文章信息/Info

Title:
Effect of Zinc on Prevention and Treatment of Radiation Oropharyngeal Mucositis in Patients with Nasopharyngeal Carcinoma Treated with Concurrent Chemoradiotherapy
文章编号:
1006-1959(2019)17-0063-05
作者:
龚建忠韦 燕潘琦津陈彦帆张 芸林小梅宁春玉杨秋燕
贵港市人民医院/广西医科大学第八附属医院肿瘤科,广西 贵港 537100
Author(s):
GONG Jian-zhongWEI YanPAN Qi-jinCHEN Yan-fanZHANG YunLIN Xiao-meiNING Chun-yuYANG Qiu-yan
Department of Oncology,Guigang People's Hospital/The Eighth Affiliated Hospital of Guangxi Medical University, Guigang 537100,Guangxi,China
关键词:
鼻咽癌放疗化疗放射性口咽炎
Keywords:
Key words:ZincNasopharyngeal carcinomaRadiotherapyChemotherapyRadioactive oropharyngeal mucositis
分类号:
R739.63
DOI:
10.3969/j.issn.1006-1959.2019.17.020
文献标志码:
A
摘要:
目的 评价锌剂防治接受同步放化疗鼻咽癌患者放射性口咽炎(OM)的效果。方法 本研究为单中心、前瞻性、非盲法随机对照临床试验,2014年10月~2017年2月入组我院98例接受同步放化疗Ⅱ~Ⅳa期鼻咽癌患者,随机分为补锌组(n=50)和对照组(n=48)。所有患者采用适型调强放射技术(IMRT)放疗,且至少行1周期同步顺铂(80~100 mg/m2,3周/次)化疗。补锌组从放疗开始至放疗结束后2周给予葡萄糖酸锌片口服,对照组采取空白处理。放疗开始后隔天记录两组患者口咽黏膜的损伤程度及疼痛程度并记录放射性OM出现的时间及放射剂量。结果 补锌组及对照组放射性OM发生率分别为96.00%及 95.83%,差异无统计学意义(P>0.05);补锌组严重放射性OM发生率为36.00%,低于对照组的60.42%,差异有统计学意义(P<0.05)。补锌组发生放射性OM平均时间为(16.50±5.73)d,大于对照组的(12.73±3.51)d,差异有统计学意义(P<0.05);补锌组严重OM的平均持续时间为(8.81±3.01)d,短于对照组的(12.12±3.89)d,差异有统计学意义(P<0.05)。补锌组口咽部疼痛较对照组轻,差异有统计学意义(P<0.05)。结论 补锌治疗对减少接受同步放化疗鼻咽癌患者发生严重OM,并缩短其持续时间,推迟发生OM时间,减少口咽部疼痛程度,值得临床进一步研究。
Abstract:
Abstract:Objective To evaluate the effect of zinc on the prevention and treatment of radiation-induced oropharyngeal mucositis(OM) in patients undergoing concurrent chemoradiotherapy for nasopharyngeal carcinoma.Methods This study was a single-center, prospective, unblinded randomized controlled clinical trial. From October 2014 to February 2017, 98 patients with concurrent chemoradiotherapy with stage II~IVa nasopharyngeal carcinoma were enrolled in our hospital. Zinc group (n=50) and control group (n=48). All patients received radiotherapy with moderate intensity modulated radiation (IMRT) and synchronized with at least one cycle of cisplatin (80-100 mg/m2,3 weeks/time). The zinc supplementation group was given orally with zinc gluconate tablets from the start of radiotherapy to 2 weeks after the end of radiotherapy. The control group was treated with a blank. The degree of injury and pain of the oropharyngeal mucosa of the two groups were recorded every other day after the start of radiotherapy and the time and dose of radioactive OM were recorded.Results The incidence of radioactive OM in the zinc supplementation group and the control group were 96.00% and 95.83%, respectively,the difference was not statistically significant (P>0.05). However, the incidence of severe radioactive OM in the zinc supplementation group was 36.00%, which was lower than that of the control group 60.42%,the difference was statistically significant (P<0.05). The average time of radioactive OM in the zinc supplementation group was (16.50±5.73) d, which was greater than that of the control group (12.73±3.51) d, the difference was statistically significant (P<0.05). The average duration of severe OM in the zinc supplementation group was (8.81±3.01)d was shorter than the control group (12.12±3.89)d,the difference was statistically significant (P<0.05). The oropharyngeal pain of the zinc supplementation group was less than that of the control group,the difference was statistically significant (P<0.05).Conclusion Zinc supplementation is worthy of further clinical study in reducing the incidence of severe OM in patients with nasopharyngeal carcinoma receiving concurrent chemoradiotherapy, shortening its duration, delaying the onset of OM, and reducing the degree of oropharyngeal pain.

参考文献/References:

[1]Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA,2018(12):1-31. [2]Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA,2016,66(2):115-132. [3]Leong YH,Soon YY,Lee KM,et al.Long-term outcomes after reirradiation in nasopharyngeal carcinoma with intensity-modulated radiotherapy:A meta-analysis[J].Head Neck,2018,40(3):622-631. [4]Liang SB,Wang Y,Hu XF,et al.Survival and Toxicities of IMRT Based on the RTOG Protocols in Patients with Nasopharyngeal Carcinoma from the Endemic Regions of China[J].J Cancer,2017,8(18):3718-3724. [5]Lin LC,Que J,Lin LK,et al.Zinc supplementation to improve mucositis and dermatitis in patients after radiotherapy for head-and-neck cancers:a double-blind,randomized study[J].Int J Radiat Oncol Biol Phys,2006,65(3):745-750. [6]Suzuki A,Kobayashi R,Shakui T,et al.Effect of polaprezinc on oral mucositis,irradiation period,and time to discharge in patientswith head and neck cancer[J].Head Neck,2016,38(9):1387-1392. [7]Doi H,Fujiwara M,Suzuki H,et al.Polaprezinc reduces the severity of radiation-induced mucositis in head and neck cancer patients[J].Mol Clin Oncol,2015,3(2):381-386. [8]Tao Z,Gao J,Qian L,et al.Factors associated with acute oral mucosal reaction induced by radiotherapy in head and neck squamous cell carcinoma:A retrospective single-center experience[J].Medicine(Baltimore),2017,96(50):e8446. [9]Maria OM,Eliopoulos N,Muanza T.Radiation-Induced Oral Mucositis[J].Front Oncol,2017(7):89. [10]Livingstone C.Zinc:physiology,deficiency,and parenteral nutrition[J].Nutr Clin Pract,2015,30(3):371-382. [11]Bao ZX,Yang XW,Shi J,et al.Serum zinc levels in 368 patients with oral mucosal diseases:A preliminary study[J].Med Oral Patol Oral Cir Bucal,2016,21(3):e335-e340. [12]Mitsuhashi H,Suemaru K,Li B,et al.Evaluation of topical external medicine for 5-fluorouracil-induced oral mucositis in hamsters[J].Eur J Pharmacol,2006,551(1-3):152-155. [13]Hayashi H,Kobayashi R,Suzuki A,et al.Preparation and clinical evaluation of a novel lozenge containing polaprezinc,a zinc-L-carnosine,for prevention of oral mucositis in patients with hematological cancer who received high-dose chemotherapy[J].Med Oncol,2016,33(8):91. [14]Hayashi H,Kobayashi R,Suzuki A,et al.Polaprezinc prevents oral mucositis in patients treated with high-dose chemotherapy followed by hematopoietic stem cell transplantation[J].Anticancer Res,2014,34(12):7271-7277. [15]Lin YS,Lin LC,Lin SW,et al.Discrepancy of the effects of zinc supplementation on the prevention of radiotherapy-induced mucositis between patients with nasopharyngeal carcinoma and those with oral cancers:subgroup analysis of a double-blind,randomized study[J].Nutr Cancer,2010,62(5):682-691. [16]Sangthawan D,Phungrassami T,Sinkitjarurnchai W.A randomized double-blind,placebo-controlled trial of zinc sulfate supplementation for alleviation of radiation-induced oral mucositis and pharyngitis in head and neck cancer patients[J].J Med Assoc Thai,2013,96(1):69-76. [17]Mirabile A,Airoldi M,Ripamonti C,et al.Pain management in head and neck cancer patients undergoing chemo-radiotherapy:Clinical practical recommendations[J].Crit Rev Oncol Hematol,2016(99):100-106.

相似文献/References:

[1]林康杰,杨小敏.影响鼻咽癌放疗敏感性相关基因研究进展[J].医学信息,2018,(22):26.[doi:10.3969/j.issn.1006-1959.2018.22.009]
 LIN Kang-jie,YANG Xiao-min.Advances in Research on Genes Related to Radiotherapy Sensitivity of Nasopharyngeal Carcinoma[J].Medical Information,2018,(17):26.[doi:10.3969/j.issn.1006-1959.2018.22.009]
[2]邓劲松,蒲泽晏,李祥坤.不同年龄人群全血锌含量结果分析[J].医学信息,2018,(23):128.[doi:10.3969/j.issn.1006-1959.2018.23.036]
 DENG Jin-song,PU Ze-yan,LI Xiang-kun.Analysis of Total Blood Zinc Content in Different Age Groups[J].Medical Information,2018,(17):128.[doi:10.3969/j.issn.1006-1959.2018.23.036]

更新日期/Last Update: 2019-09-01